Amphastar Pharmaceuticals, Inc. (AMPH)
25.14
-0.90
(-3.46%)
USD |
NASDAQ |
Oct 23, 16:00
25.00
-0.14
(-0.56%)
After-Hours: 20:00
Amphastar Pharmaceuticals Enterprise Value : 1.465B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.465B |
| October 22, 2026 | 1.503B |
| October 21, 2026 | 1.510B |
| October 20, 2026 | 1.499B |
| October 19, 2026 | 1.508B |
| October 16, 2026 | 1.496B |
| October 15, 2026 | 1.519B |
| October 14, 2026 | 1.505B |
| October 13, 2026 | 1.504B |
| October 12, 2026 | 1.534B |
| October 09, 2026 | 1.528B |
| October 08, 2026 | 1.494B |
| October 07, 2026 | 1.482B |
| October 06, 2026 | 1.498B |
| October 05, 2026 | 1.475B |
| October 02, 2026 | 1.477B |
| October 01, 2026 | 1.474B |
| September 30, 2026 | 1.494B |
| September 29, 2026 | 1.531B |
| September 28, 2026 | 1.561B |
| September 25, 2026 | 1.507B |
| September 24, 2026 | 1.513B |
| September 23, 2026 | 1.457B |
| September 22, 2026 | 1.430B |
| September 21, 2026 | 1.437B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.400B |
| September 17, 2026 | 1.409B |
| September 16, 2026 | 1.414B |
| September 15, 2026 | 1.401B |
| September 14, 2026 | 1.413B |
| September 11, 2026 | 1.407B |
| September 10, 2026 | 1.397B |
| September 09, 2026 | 1.376B |
| September 08, 2026 | 1.371B |
| September 04, 2026 | 1.382B |
| September 03, 2026 | 1.410B |
| September 02, 2026 | 1.405B |
| September 01, 2026 | 1.372B |
| August 31, 2026 | 1.354B |
| August 28, 2026 | 1.332B |
| August 27, 2026 | 1.326B |
| August 26, 2026 | 1.332B |
| August 25, 2026 | 1.331B |
| August 24, 2026 | 1.311B |
| August 21, 2026 | 1.314B |
| August 20, 2026 | 1.318B |
| August 19, 2026 | 1.320B |
| August 18, 2026 | 1.303B |
| August 17, 2026 | 1.283B |
| August 14, 2026 | 1.285B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Viatris, Inc. | 33.01B |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
| Merck & Co., Inc. | 405.39B |
| Pfizer Inc. | 222.94B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 30.35M |
| Revenue (Quarterly) | 183.90M |
| Total Expenses (Quarterly) | 153.56M |
| EPS Diluted (Quarterly) | 0.6862 |
| Gross Profit Margin (Quarterly) | 48.73% |
| Profit Margin (Quarterly) | 16.50% |
| Earnings Yield | 6.79% |
| Operating Earnings Yield | 9.80% |
| Normalized Earnings Yield | 6.010 |